Cytokinetics, Inc. (CYTK) Reports In-Line Q2 Loss of 13c/Share
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $70.52 +1.80%
EPS Growth %: -45.5%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: -45.5%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13).
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- H.C. Wainwright Reiterates Buy Rating on Anixa Biosciences (ANIX)
- Barclays Downgrades Travelers (TRV) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
